Tekla Life Sciences Investors Statistics
Share Statistics
Tekla Life Sciences Investors has - shares outstanding. The number of shares has increased by 4.34% in one year.
| Shares Outstanding | - |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 27.15M |
| Failed to Deliver (FTD) Shares | 1 |
| FTD / Avg. Volume | 0% |
Short Selling Information
The latest short interest is 74.12K, so 0.27% of the outstanding shares have been sold short.
| Short Interest | 74.12K |
| Short % of Shares Out | 0.27% |
| Short % of Float | 0.27% |
| Short Ratio (days to cover) | 0.41 |
Valuation Ratios
The PE ratio is 4.96 and the forward PE ratio is null.
| PE Ratio | 4.96 |
| Forward PE | null |
| PS Ratio | 4.88 |
| Forward PS | null |
| PB Ratio | 0.92 |
| P/FCF Ratio | 0 |
| PEG Ratio | n/a |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Tekla Life Sciences Investors.
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0, with a Debt / Equity ratio of 0.
| Current Ratio | 0 |
| Quick Ratio | 0 |
| Debt / Equity | 0 |
| Total Debt / Capitalization | 0 |
| Cash Flow / Debt | 0 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is 0.19% and return on capital (ROIC) is 0%.
| Return on Equity (ROE) | 0.19% |
| Return on Assets (ROA) | 0.19% |
| Return on Capital (ROIC) | 0% |
| Revenue Per Employee | - |
| Profits Per Employee | - |
| Employee Count | - |
| Asset Turnover | 0.19 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -5.76% in the last 52 weeks. The beta is 0.7, so Tekla Life Sciences Investors's price volatility has been higher than the market average.
| Beta | 0.7 |
| 52-Week Price Change | -5.76% |
| 50-Day Moving Average | 14.03 |
| 200-Day Moving Average | 14.32 |
| Relative Strength Index (RSI) | 39.94 |
| Average Volume (20 Days) | 95.58K |
Income Statement
In the last 12 months, Tekla Life Sciences Investors had revenue of 86.69M and earned 85.30M in profits. Earnings per share was 0.
| Revenue | 86.69M |
| Gross Profit | 86.69M |
| Operating Income | 0 |
| Net Income | 85.30M |
| EBITDA | 0 |
| EBIT | n/a |
| Earnings Per Share (EPS) | 0 |
Balance Sheet
The company has 1 in cash and 0 in debt, giving a net cash position of 1.
| Cash & Cash Equivalents | 1 |
| Total Debt | 0 |
| Net Cash | 1 |
| Retained Earnings | 44.13M |
| Total Assets | 460.58M |
| Working Capital | 1 |
Cash Flow
In the last 12 months, operating cash flow was 0 and capital expenditures 0, giving a free cash flow of 0.
| Operating Cash Flow | 0 |
| Capital Expenditures | 0 |
| Free Cash Flow | 0 |
| FCF Per Share | null |
Margins
Gross margin is 100%, with operating and profit margins of 0% and 98.4%.
| Gross Margin | 100% |
| Operating Margin | n/a |
| Pretax Margin | 98.4% |
| Profit Margin | 98.4% |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
HQL pays an annual dividend of $2, which amounts to a dividend yield of 14.89%.
| Dividend Per Share | $2.00 |
| Dividend Yield | 14.89% |
| Dividend Growth (YoY) | 66.67% |
| Payout Ratio | 65.79% |
| Earnings Yield | 0% |
| FCF Yield | 0% |
Analyst Forecast
Currently there are no analyst rating for HQL.
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
Scores
| Altman Z-Score | 250.42 |
| Piotroski F-Score | 2 |